This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
Cercare Medical Receives FDA 510(k) Clearance for AI-Powered Brain Tumor Segmentation
-
Development of a multidimensional diagnostic model integrating cfDNA methylation and clinical parameters for colorectal cancer and precancerous lesions using artificial intelligence.
Li-Yue Sun et al.. Journal of Clinical Oncology, 2026.
DOI: 10.1200/JCO.2026.44.19_suppl.94
-
Longitudinal Analysis of Changes in Deep Learning Image-based Breast Cancer Risk Scores over Time
Constance Lehman et al.. Radiology, 2026.
DOI: 10.1148/radiol.253023
Weekly News Brief: June 29–July 3, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of June 29–July 3, 2026.
This week’s brief covers an FDA-cleared AI tool for brain tumor segmentation, a machine-learning model for accessible colorectal cancer screening, and a study showing AI mammogram risk scores can rise years before a breast cancer diagnosis.
To learn more about Oncology Virtual Expert, read "FDA Clears AI Module for Brain Tumor Segmentation," or see the press release.
For more information on the cfDNA methylation–based model, read "Multimodal Machine Learning May Improve Access to Colorectal Cancer Screening," or see the abstract.
To learn more about trajectories of mammogram AI risk scores, read "Deep Learning Risk Scores From Mammograms Show Rising Trajectory Years Before Breast Cancer Diagnosis," or see the source report in Radiology.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.